Guest lecture - Sylvie Claeysen
Multi-target-directed ligands (MTDL) against Alzheimer's disease: dual 5-HT4 receptor agonists/acetylcholinesterase inhibitors.
Sylvie Claeysen has developed programs in molecular pharmacology on 5-HT4 receptor (activation mechanisms, dimerization, function…), and is now driving the entire Research project concerning the 5-HT4 receptor in Montpellier after the retirement of A. Dumuis, who originally discovered this receptor in 1988.
She recently focused on a novel project, of which the ultimate aim is to validate a new therapeutic target in the Alzheimer’s disease context. It relies on an original approach aimed at unbalancing APP maturation towards a nonamyloidogenic protective pathway, by controlling APP traffic and α-secretase cleavage.
This view of α-secretase control by a GPCR is particularly promising.